vTv Therapeutics (VTVT)
(Delayed Data from NSDQ)
$13.13 USD
-0.22 (-1.65%)
Updated Sep 27, 2024 02:23 PM ET
After-Market: $13.86 +0.73 (5.56%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for vTv Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 2 | 4 | 6 | 3 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 2 | 4 | 6 | 3 |
Selling & Adminstrative & Depr. & Amort Expenses | 26 | 25 | 26 | 18 | 24 |
Income After Depreciation & Amortization | -26 | -23 | -22 | -12 | -21 |
Non-Operating Income | 0 | -2 | 4 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 1 | 2 |
Pretax Income | -26 | -25 | -18 | -13 | -22 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | -6 | -6 | -5 | -4 | -9 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -26 | -25 | -18 | -13 | -22 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -20 | -19 | -13 | -9 | -13 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -25 | -22 | -22 | -11 | -20 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 1 |
Income After Depreciation & Amortization | -26 | -23 | -22 | -12 | -21 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2.09 | 1.87 | 1.52 | 1.18 | 0.76 |
Diluted EPS Before Non-Recurring Items | -9.71 | -10.40 | -5.60 | -6.80 | -14.80 |
Diluted Net EPS (GAAP) | -9.71 | -10.40 | -8.40 | -7.20 | -23.60 |
Fiscal Year end for vTv Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 7.16 | 6.63 | 4.71 | 5.36 | 8.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | -7.16 | -5.63 | -4.71 | -5.36 | -8.00 |
Non-Operating Income | 0.75 | -0.29 | 0.27 | -3.17 | 0.79 |
Interest Expense | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
Pretax Income | -6.41 | -5.92 | -4.44 | -8.54 | -7.21 |
Income Taxes | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 |
Minority Interest | -1.23 | -1.15 | -0.96 | -1.89 | -1.59 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -6.41 | -6.02 | -4.44 | -8.54 | -7.21 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -5.18 | -4.87 | -3.48 | -6.65 | -5.62 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 6.40 | 4.14 | 2.09 | 2.04 | 2.04 |
Diluted EPS Before Non-Recurring Items | -0.81 | -1.17 | -1.67 | -3.20 | -2.80 |
Diluted Net EPS (GAAP) | -0.81 | -1.17 | -1.31 | -3.20 | -2.80 |